With standout facilities and strong industry links, the School prepares students for careers in health and medical science.
Excludes commercial-in-confidence projects.
Research since 2008 is shown below.
Open access indicates that an output is open access.
Diab, S, Abdelaziz, AM, Li, P, Teo, T, Basnet, SK, Noll, B, Rahaman, MH, Lu, J, Hou, J, Yu, M, Le, BT, Albrecht, H, Milne, RW & Wang, S 2017, 'Dual inhibition of Mnk2 and FLT3 for potential treatment of acute myeloid leukaemia', European journal of medicinal chemistry, in press, pp. 1-27.
O'Brien-Brown, J, Jackson, A, Reekie, TA, Barron, ML, Werry, EL, Schiavini, P, McDonnell, M, Munoz, L, Wilkinson, S, Noll, B, Wang, S & Kassiou, M 2017, 'Discovery and pharmacological evaluation of a novel series of adamantyl cyanoguanidines as P2X7 receptor antagonists', European journal of medicinal chemistry, vol. 130, pp. 433-439.
1 1 3
Tadesse, S, Yu, M, Mekonnen, LB, Lam, F, Islam, S, Tomusange, K, Rahaman, MH, Noll, B, MC Basnet, S, Teo, T, Albrecht, H, Milne, R & Wang, S 2017, 'Highly potent, selective, and orally bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine cyclin-dependent kinases 4 and 6 inhibitors as anticancer drug candidates: design, synthesis, and evaluation', Journal of medicinal chemistry, vol. 60, no. 5, pp. 1892-1915.
Sutton, SK, Carter, DR, Kim, P, Tan, O, Arndt, GM, Zhang, XD, Baell, J, Noll, BD, Wang, S, Kumar, N, McArthur, GA, Cheung, BB & Marshall, GM 2016, 'A novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent manner', Oncotarget, vol. 7, no. 32, pp. 52166-52178.
Open access 1
External engagement & recognition
|Peter MacCallum Cancer Centre||AUSTRALIA|
|Sydney Children's Hospital||AUSTRALIA|
|University of New South Wales||AUSTRALIA|
|University of Newcastle||AUSTRALIA|
|University of South Australia||AUSTRALIA|
|University of Sydney||AUSTRALIA|
|Zhejiang Agricultural and Forestry University||CHINA (EXCLUDES SARS AND TAIWA|